Major bleeds rise with perioperative aspirin for non-cardiac surgery

March 31, 2014, American College of Cardiology

Patients given aspirin to prevent heart problems after non-heart-related surgery had a higher risk of serious bleeding than the patients who did not receive aspirin. At the same time, aspirin did not reduce incidence of post-operative heart attacks and death, according to data from POISE-2 presented at the American College of Cardiology's 63rd Annual Scientific Session. POISE-2 is the largest clinical trial focused on major cardiovascular complications in non-cardiac surgery.

Although many guidelines address prophylactic in a surgical setting, the focus is largely on cardiac surgery. Little guidance is available for undergoing non-cardiac surgery. This phase III trial followed earlier evidence suggesting that small doses of aspirin and clonidine can ward off heart attacks and heart-related death for such patients. Data for clonidine are to be presented separately at ACC.14.

POISE-2 enrolled 10,011 patients in 23 countries and grouped them by aspirin use: those who had been taking any dose daily for four of the six weeks before surgery, which became the continuation stratum, and those who had not, the initiation stratum. For the continuation stratum, aspirin use was stopped at least 72 hours before surgery. All patients received placebo or 200 mg aspirin just before surgery. The initiation stratum continued 100 mg aspirin or placebo daily for 30 days. The continuation stratum received 100 mg aspirin or placebo for seven days and then resumed their previous aspirin regimen. The primary endpoint of death and non-fatal heart attack at 30 days was no different between the two groups (7 percent in the aspirin group and 7.1 percent in the placebo group); however, major was significantly higher in aspirin-treated patients than in the placebo group (4.6 percent vs. 3.7 percent). The primary and secondary outcomes were similar in the two aspirin strata.

"POISE-2 demonstrated that adding aspirin on top of prophylactic anticoagulants in patients who are having non- is not beneficial," said P.J. Devereaux, M.D., Ph.D., associate professor of clinical epidemiology and biostatistics at McMaster University, and lead investigator for the study. "An important caveat is that 65 percent of our patients were on prophylactic anticoagulants."

There is strong evidence that aspirin prevents perioperative blood clots in veins if an anticoagulant isn't given, he noted. No subgroup effects were seen for vascular versus non-vascular surgery or baseline risk according to the Revised Cardiac Risk Index.

With major bleeding known to increase the likelihood of post-surgical heart attack and a post-hoc POISE-2 regression analysis demonstrating this relationship, researchers considered why their study found a higher risk for bleeding but not for . "One possibility is that aspirin did prevent some heart attacks, but we were causing enough bleeding to nullify that benefit," Devereaux said. The study used clinical measurements for maximum reliability in identifying heart attacks, because symptoms are masked by pain-killing drugs in more than 50 percent of patients who have heart attacks after surgery.

According to data analysis, the absolute risk increase for life-threatening and with aspirin treatment drops from about 1.2 percent on the day of to 0.9 percent by day four and to 0.3 by day eight. At about the eighth day, the risk returns to normal. This information will help doctors weigh benefits versus potential risks when aspirin might be indicated post-surgically, Devereaux said.

"We're confirming a finding that bleeding itself can cause heart attacks," he said. "We need to find a better way to prevent bleeding so we can get back to how to prevent some of these thrombotic events." Patients will be followed for a year, and one-year data will be analyzed.

Although POISE-2 is a large trial by perioperative standards, the lower (0.86) and upper (1.15) boundary of the hazard ratio for the primary outcome identifies that the possibility of appreciable benefit or harm has not been excluded, Devereaux said.

Explore further: Bedtime aspirin may reduce risk of morning heart attack

Related Stories

Bedtime aspirin may reduce risk of morning heart attack

November 19, 2013
Taking aspirin at bedtime instead of in the morning might reduce acute heart events, according a new study presented at the American Heart Association's Scientific Sessions 2013.

OK to continue aspirin therapy up to pancreatic surgery

August 1, 2013
(HealthDay)—Patients on aspirin therapy do not have higher rates of perioperative bleeding, transfusion, or major procedure-related complications following elective pancreatic surgery, according to research published online ...

Daily aspirin may guard against ovarian cancer

February 6, 2014
(HealthDay)—Taking aspirin every day might lower a woman's risk of developing ovarian cancer by one-fifth, a new study suggests.

A shorter interruption of anti-thrombotics does not influence peri-operative complications

September 1, 2013
A shortened pre-surgical interruption of anti-thrombotic therapy, compared to the more traditional one-week interruption, has no influence on perioperative complications in cardiac patients, according to the results of the ...

Preoperative aspirin therapy can benefit cardiac surgery patients

December 5, 2011
Aspirin taken within five days of cardiac surgery is associated with a significant decrease in the risk of major postoperative complications, including renal failure, a lengthy intensive care unit stay and even early death ...

Even low-dose aspirin may increase risk of GI bleeding

September 12, 2011
The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer. According to a new study in Clinical ...

Recommended for you

Researchers borrow from AIDS playbook to tackle rheumatic heart disease

January 22, 2018
Billions of US taxpayer dollars have been invested in Africa over the past 15 years to improve care for millions suffering from the HIV/AIDS epidemic; yet health systems on the continent continue to struggle. What if the ...

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.